150 related articles for article (PubMed ID: 19794230)
1. L-valine ester of cyclopropavir: a new antiviral prodrug.
Wu Z; Drach JC; Prichard MN; Yanachkova M; Yanachkov I; Bowlin TL; Zemlicka J
Antivir Chem Chemother; 2009 Sep; 20(1):37-46. PubMed ID: 19794230
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir.
Li C; Quenelle DC; Prichard MN; Drach JC; Zemlicka J
Bioorg Med Chem; 2012 Apr; 20(8):2669-74. PubMed ID: 22417649
[TBL] [Abstract][Full Text] [Related]
3. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.
Kim I; Song X; Vig BS; Mittal S; Shin HC; Lorenzi PJ; Amidon GL
Mol Pharm; 2004; 1(2):117-27. PubMed ID: 15832508
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
Jung D; Dorr A
J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
[TBL] [Abstract][Full Text] [Related]
5. Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity.
Mhaske SB; Ksebati B; Prichard MN; Drach JC; Zemlicka J
Bioorg Med Chem; 2009 Jun; 17(11):3892-9. PubMed ID: 19410465
[TBL] [Abstract][Full Text] [Related]
6. Improved Protease-Targeting and Biopharmaceutical Properties of Novel Prodrugs of Ganciclovir.
Sun K; Xu H; Hilfinger JL; Lee KD; Provoda CJ; Sabit H; Amidon GL
Mol Pharm; 2018 Feb; 15(2):410-419. PubMed ID: 29251944
[TBL] [Abstract][Full Text] [Related]
7. Cyclopropanecarboxylic acid esters as potential prodrugs with enhanced hydrolytic stability.
Bender DM; Peterson JA; McCarthy JR; Gunaydin H; Takano Y; Houk KN
Org Lett; 2008 Feb; 10(3):509-11. PubMed ID: 18181639
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
9. Validation of microdialysis sampling for oral availability studies by means of a new ganciclovir prodrug.
Lindén K; Zhou XX; Ståble L
Pharmacol Toxicol; 2002 Jun; 90(6):297-302. PubMed ID: 12403050
[TBL] [Abstract][Full Text] [Related]
10. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.
Han HK; Oh DM; Amidon GL
Pharm Res; 1998 Sep; 15(9):1382-6. PubMed ID: 9755889
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
Eriksson U; Hilfinger JM; Kim JS; Mitchell S; Kijek P; Borysko KZ; Breitenbach JM; Drach JC; Kashemirov BA; McKenna CE
Bioorg Med Chem Lett; 2007 Feb; 17(3):583-6. PubMed ID: 17161946
[TBL] [Abstract][Full Text] [Related]
12. Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals.
Krecmerova M
Mini Rev Med Chem; 2017; 17(10):818-833. PubMed ID: 28215138
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase.
Lai L; Xu Z; Zhou J; Lee KD; Amidon GL
J Biol Chem; 2008 Apr; 283(14):9318-27. PubMed ID: 18256025
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir.
Patel K; Trivedi S; Luo S; Zhu X; Pal D; Kern ER; Mitra AK
Int J Pharm; 2005 Nov; 305(1-2):75-89. PubMed ID: 16242278
[TBL] [Abstract][Full Text] [Related]
15. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Manuel O; Perrottet N; Pascual M
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
18. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo.
Lorenzi PL; Landowski CP; Song X; Borysko KZ; Breitenbach JM; Kim JS; Hilfinger JM; Townsend LB; Drach JC; Amidon GL
J Pharmacol Exp Ther; 2005 Aug; 314(2):883-90. PubMed ID: 15901797
[TBL] [Abstract][Full Text] [Related]
19. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design.
Tirucherai GS; Dias C; Mitra AK
J Ocul Pharmacol Ther; 2002 Dec; 18(6):535-48. PubMed ID: 12537680
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus protease targeted prodrug development.
Sabit H; Dahan A; Sun J; Provoda CJ; Lee KD; Hilfinger JH; Amidon GL
Mol Pharm; 2013 Apr; 10(4):1417-24. PubMed ID: 23485093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
